Jefferies Cuts Price Target on Bristol-Myers Squibb (BMY) to $57; Reiterates hold

September 12, 2016 7:30 AM EDT
Get Alerts BMY Hot Sheet
Price: $57.04 +3.28%

Rating Summary:
    10 Buy, 12 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade BMY Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies reiterated a Hold rating on Bristol-Myers Squibb Co. (NYSE: BMY), and cut the price target to $57.00 (from $69.00). Jefferies believes that the market could see worse than expected data from CM-026 and CM-568 as well as better than expected data from AZN's MYSTIC study and Roche's Chemo-IO studies in 2017.

Analyst Jeffrey Holford commented, "We see a difficult catalyst set for BMY with numerous competitor read outs in NSCLC as well as further downside to expectations for CM-026, CM-568 and CM-227. The market under-estimates AZN's MYSTIC study as well as Roche's Chemo-IO studies in our view. We model EPS up to 12% lower than consensus mid term. We strongly prefer risk-reward from Immuno-Oncology exposure through AZN (upgraded to Buy today) over BMY."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $55.66 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment